FOXA1 and breast cancer: It has been recently reported that FOXA1/GRHL2 collaboration could establish a targetable pathway in endocrine therapy-resistant breast cancer (Cocce et al., 2019), and facilitate depositing H3K4me1 at potential enhancer elements by recruiting the chromatin modifier MLL3 (Jozwik et al., 2016).